- Home
- DHR vs SNY Comparison
DHR vs SNY Comparison
Compare DHR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHR
- SNY
- Stock Information
- Founded
- DHR 1969
- SNY 1994
- Country
- DHR United States
- SNY France
- Employees
- DHR N/A
- SNY N/A
- Industry
- DHR Industrial Machinery/Components
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- DHR Industrials
- SNY Health Care
- Exchange
- DHR Nasdaq
- SNY Nasdaq
- Market Cap
- DHR 135.9B
- SNY 123.6B
- IPO Year
- DHR N/A
- SNY N/A
- Fundamental
- Price
- DHR $189.58
- SNY $49.90
- Analyst Decision
- DHR Strong Buy
- SNY Buy
- Analyst Count
- DHR 18
- SNY 2
- Target Price
- DHR $264.88
- SNY $62.50
- AVG Volume (30 Days)
- DHR 3.9M
- SNY 3.1M
- Earning Date
- DHR 04-22-2025
- SNY 04-24-2025
- Dividend Yield
- DHR 0.68%
- SNY 3.21%
- EPS Growth
- DHR N/A
- SNY 39.56
- EPS
- DHR 5.16
- SNY 5.45
- Revenue
- DHR $23,820,000,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- DHR $3.53
- SNY $5.35
- Revenue Next Year
- DHR $6.77
- SNY $6.69
- P/E Ratio
- DHR $36.75
- SNY $18.73
- Revenue Growth
- DHR 0.35
- SNY N/A
- 52 Week Low
- DHR $171.00
- SNY $45.80
- 52 Week High
- DHR $281.70
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- DHR 43.59
- SNY 37.47
- Support Level
- DHR $189.67
- SNY $51.67
- Resistance Level
- DHR $197.77
- SNY $55.73
- Average True Range (ATR)
- DHR 5.28
- SNY 0.89
- MACD
- DHR 0.17
- SNY -0.12
- Stochastic Oscillator
- DHR 1.58
- SNY 0.34
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.